down arrow

Heron Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4277461020
USD
1.31
0.14 (11.97%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Black Diamond Therapeutics, Inc.
Harpoon Therapeutics, Inc.
Stoke Therapeutics, Inc.
Graphite Bio, Inc.
X4 Pharmaceuticals, Inc.
Heron Therapeutics, Inc.
Mersana Therapeutics, Inc.
Selecta Biosciences, Inc.
InflaRx NV
Vaxxinity, Inc.
Gritstone bio, Inc.
Why is Heron Therapeutics, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Operating profit has grown by an annual rate 14.95% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -77.04
2
Risky - Negative EBITDA
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -4.39%, its profits have risen by 90.4%
3
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -4.39% returns in the last 1 year, the stock has also underperformed S&P 500 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Heron Therapeutics, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Heron Therapeutics, Inc.
11.02%
-0.86
81.78%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
3.54%
EBIT Growth (5y)
14.95%
EBIT to Interest (avg)
-77.04
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-4.45
Sales to Capital Employed (avg)
0.95
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-11.26
EV to EBIT
-124.99
EV to EBITDA
-365.76
EV to Capital Employed
4.56
EV to Sales
3.01
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-3.64%
ROE (Latest)
Negative BV
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company
NET PROFIT(HY)

Higher at USD 0.45 MM

RAW MATERIAL COST(Y)

Fallen by -3.87% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -499.34 %

-6What is not working for the Company
INTEREST(9M)

At USD 5.43 MM has Grown at 73.49%

CASH AND EQV(HY)

Lowest at USD 91.31 MM

INVENTORY TURNOVER RATIO(HY)

Lowest at 0.66 times

Here's what is working for Heron Therapeutics, Inc.
Net Profit
At USD 0.45 MM has Grown at 103.66%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (USD MM)

Net Profit
Higher at USD 0.45 MM
than preceding 12 month period ended Jun 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Debt-Equity Ratio
Lowest at -499.34 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by -3.87% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Heron Therapeutics, Inc.
Interest
At USD 5.43 MM has Grown at 73.49%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Cash and Eqv
Lowest at USD 91.31 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Inventory Turnover Ratio
Lowest at 0.66 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."